Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,123 across all filing types
Latest filing 2025-03-18 Earnings Release
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
POSITIVE PROFIT ALERT
Earnings Release Classification · 1% confidence The document is a “Positive Profit Alert” issued under HKEX Listing Rule 13.09(2). It provides preliminary, unaudited consolidated net profit guidance for the year ended 31 December 2024, giving key highlights (turn from loss to profit and main drivers) ahead of the formal results announcement. This is not the full audited annual report or interim report, nor an AGM pack, nor a notice of dividend or share issue. It is an initial announcement of periodical financial performance results (preliminary annual earnings guidance), which aligns with an Earnings Release (ER) rather than a fallback regulatory notice (RNS) or report publication announcement (RPA). FY 2024
2025-03-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short, sub-5,000 character announcement notifying investors of the date of a board meeting to consider and approve the Group’s annual results. It does not contain the actual results, nor any changes to management, nor is it a proxy or AGM information. It is not the report itself, but a regulatory notice. Since there is no specific category for “Notice of Board Meeting” in the taxonomy, this falls into the fallback “Regulatory Filings” category (RNS).
2025-03-17 English
DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION AND ACQUISITION OF NOTES
Capital/Financing Update Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement by CMBC Capital Holdings Limited regarding a discloseable transaction under Chapter 14 of the Listing Rules. It details the subscription and acquisition of debt notes (Notes 1 and Notes 2), including amounts, terms, issuance, and implications under the Listing Rules. This is a financing activity announcement rather than a full report, management discussion, call transcript, or share issuance. It neatly fits the definition of a Capital/Financing Update (CAP).
2025-03-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025
Regulatory Filings Classification · 1% confidence The document is a standardized monthly return (Form FF301) filed under HKEX Listing Rules (Chapter 19B) summarizing movements in authorised and issued share capital and related share instruments. It is a regulatory submission to the exchange, not an AGM presentation, earnings announcement, proxy, or a standalone annual/interim report. It does not announce a dividend, merger, or management change, nor is it a transcript or legal notice. Therefore, it falls under the general "Regulatory Filings" category (RNS).
2025-03-05 English
DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF NOTES
Regulatory Filings Classification · 1% confidence The document is an announcement under the Hong Kong Listing Rules of a discloseable transaction (the acquisition of notes). It is not a full financial report (10-K/IR), nor an earnings release, management or audit report, proxy or dividend notice, M&A or delisting notice, share issue/capital change, or insider dealing. It is a mandatory regulatory announcement that does not fit any more specific category, making it a general Regulatory Filing (RNS).
2025-02-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025
Regulatory Filings Classification · 1% confidence The document is a Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” submitted to the Hong Kong Exchange, detailing periodic movements in authorised and issued share capital and securities. It is a routine regulatory submission under the Listing Rules rather than an earnings release, capital fundraising announcement, or proxy statement. Therefore, it best fits the fallback category for miscellaneous regulatory filings.
2025-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.